Follow
E Claire Dees
E Claire Dees
Verified email at med.unc.edu
Title
Cited by
Cited by
Year
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
LA Carey, EC Dees, L Sawyer, L Gatti, DT Moore, F Collichio, DW Ollila, ...
Clinical cancer research 13 (8), 2329-2334, 2007
26202007
Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 379 (2), 111-121, 2018
15912018
Prospective validation of a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 373 (21), 2005-2014, 2015
13282015
Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study
R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ...
Journal of Clinical oncology 34 (21), 2460, 2016
12942016
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in …
HA Burris III, HI Hurwitz, EC Dees, A Dowlati, KL Blackwell, B O'Neil, ...
Journal of clinical oncology 23 (23), 5305-5313, 2005
7852005
The proteasome as a target for cancer therapy
PM Voorhees, EC Dees, B O’Neil, RZ Orlowski
Clinical cancer research 9 (17), 6316-6325, 2003
5542003
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector, W Xia, H Burris III, H Hurwitz, EC Dees, A Dowlati, B O'Neil, ...
Journal of clinical oncology 23 (11), 2502-2512, 2005
4672005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
RZ Orlowski, PM Voorhees, RA Garcia, MD Hall, FJ Kudrik, T Allred, ...
Blood 105 (8), 3058-3065, 2005
4002005
The interaction of post‐traumatic growth and post‐traumatic stress symptoms in predicting depressive symptoms and quality of life
EF Morrill, NT Brewer, SC O'Neill, SE Lillie, EC Dees, LA Carey, BK Rimer
Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2008
3402008
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ...
New England journal of medicine 380 (25), 2395-2405, 2019
3352019
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and …
B Melichar, A Adenis, AC Lockhart, J Bennouna, EC Dees, O Kayaleh, ...
The Lancet Oncology 16 (4), 395-405, 2015
2412015
American joint committee on cancer tumor–node–metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
LA Carey, R Metzger, EC Dees, F Collichio, CI Sartor, DW Ollila, ...
Journal of the National Cancer Institute 97 (15), 1137-1142, 2005
2372005
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer
EC Dees, S O'reilly, SN Goodman, S Sartorius, MA Levine, RJ Jones, ...
Cancer investigation 18 (6), 521-529, 2000
2122000
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
AA Miller, DJ Murry, K Owzar, DR Hollis, EB Kennedy, G Abou-Alfa, ...
Journal of Clinical Oncology 27 (11), 1800, 2009
2112009
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study
WJ Irvin Jr, CM Walko, KE Weck, JG Ibrahim, WK Chiu, EC Dees, ...
Journal of clinical oncology 29 (24), 3232, 2011
2092011
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study
A Partridge, K Adloff, E Blood, EC Dees, C Kaelin, M Golshan, J Ligibel, ...
Journal of the National Cancer Institute 100 (4), 243-251, 2008
1902008
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
RZ Orlowski, EC Dees
Breast Cancer Research 5, 1-7, 2002
1692002
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
HH Soliman, E Jackson, T Neuger, EC Dees, RD Harvey, H Han, ...
Oncotarget 5 (18), 8136, 2014
1642014
Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
R Nanda, LQ Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ...
Cancer research 75 (9_Supplement), S1-09-S1-09, 2015
1632015
Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors
JR Infante, EC Dees, AJ Olszanski, SV Dhuria, S Sen, S Cameron, ...
Journal of clinical oncology 32 (28), 3103-3110, 2014
1622014
The system can't perform the operation now. Try again later.
Articles 1–20